Emory University
Pharmacology and Chemical Biology and Neurology
Dr. Golde is a Professor of Pharmacology and Neurology at Emory University School of Medicine, Director of the Center for Neurodegenerative Disease (CND) and a Georgia Research Alliance Eminent Scholar. Dr. Golde has made a number of significant contributions to the Alzheimer’s field including but limited to: i) identification of the amyloid β (Aβ) protein as a normal metabolite, and demonstration that causal Alzheimer’s Disease (AD)-linked mutations alter Aβ production in a way that enhance its deposition, ii) data supporting the critical role of Aβ42 in AD and identification of drugs that selectively reduce Aβ42 iii) insights into the mechanism, promise and limitations of immunotherapies targeting Aβ and tau in AD iv) defining the complex interplay between AD relevant proteinopathies and the innate immune system, and identification of novel therapeutic approaches to targeting immune pathways in AD. He has previously held research leadership positions at Mayo Clinic and the University of Florida. Over his career he has been awarded over $60M in NIH funds. He has won numerous awards including the MetLife Award for Biomedical research and the Zenith Award from the Alzheimer’s association. He is an inventor on multiple patents and a co-founder of two biotech companies.

Moderator of 2 Sessions

PRE CONFERENCE SYMPOSIUM
Session Time
08:00 - 15:50
Session Type
PRE CONFERENCE SYMPOSIUM
Date
Tue, 28.03.2023
Room
ONSITE - HALL G3
Session Description
This day-long, CME credit-eligible workshop will provide participants with an understanding of the common and distinct features of neurodegenerative diseases, which include not only those affecting the brain, such as Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, vascular dementia, frontotemporal dementia, and mixed dementia; but also the ocular diseases including age-related macular degeneration, glaucoma, diabetic retinopathy, and inherited retinal degenerative diseases. Some questions that will be addressed during this fourth pre-symposium workshop, starting from small (Section 1. Mitochondria In Health and Neurodegeneration; and Section 2. Glucose and Lipid Metabolism) and ending with a more wholistic (Section 3. System-level Energy Dysfunction and Metabolic Disorders) point of view: •Why does the nervous system (including the brain and eyes) have a unique energy demand? •How can one evaluate metabolic fitness? •How can only tiny changes in energy, metabolism and/or mitochondria lead to neurodegenerative disease?•Is there a definite ‘tipping point’ that could be prevented in humans to delay onset of disease?•What role do comorbidities, like diabetes and other insulin/energy/metabolism-dysfunction diseases, play in neurodegenerative diseases?•How can one study this in living humans? •Are there common elements across these diseases that could give a clue to preventions and future treatments?Section 1 Summary: Mitochondria are essential organelles that regulate multiple processes essential for neuronal function including metabolic balance, intracellular calcium homeostasis, production of reactive oxygen species, and apoptotic signaling. Accumulating evidence indicates that mitochondrial defects play a central role in the pathogenesis of neurodegenerative diseases. This session will cover new insights into mitochondrial dynamics, trafficking, transmitophagy, and damage as well as novel therapeutic strategies to increase mitochondrial health in eye and brain diseases.Section 2 Summary: Individual cell-types in the brain have unique energy requirements and unique roles in meeting the energetic demands placed on the brain. Disruption in cellular cross-talk and cell-autonomous energy occur during the setting of neurodegenerative disease. A more refined disruption of the cellular and intercellular metabolic defects will likely offer new insights into neurodegenerative disease and perhaps illuminate novel therapeutic approaches.Section 3 Summary: Metabolic conditions and diabetes are risk factors for both Alzheimer’s disease and eye diseases. In addition to hypoperfusion restricting blood flow, they also impact brain energy metabolism including insulin signaling and glucose utilization. In this section, the speakers will discuss how brain metabolism and insulin signaling are impaired in these neurodegenerative conditions and how these pathways can be targeted for therapy to treat brain and eye diseases, and to promote healthy brain aging.

Supported with an educational grant by BrightFocus

Session Time
11:10 - 13:10
Session Type
SYMPOSIUM
Date
Sat, 01.04.2023
Room
ONSITE - HALL F4+F5

Presenter of 6 Presentations

HOW TO KEEP YOUR CAREER ON TRACK AND ALSO ENJOY IT

Session Type
BREAK
Date
Fri, 31.03.2023
Session Time
13:00 - 13:45
Room
EXHIBITION
Lecture Time
13:00 - 13:00

THE AMYLOID SCAFFOLD HYPOTHESIS

Session Type
SYMPOSIUM
Date
Wed, 29.03.2023
Session Time
09:10 - 11:10
Room
ONSITE - HALL F1+F2+F3
Lecture Time
09:25 - 09:40

Abstract

Abstract Body

Utilizing network-modules derived from an extensive proteomic study of human Alzheimer’s disease (AD) brains and newly generated APP CRND8 mouse brain proteomic data, we show that many of the brain proteomic changes observed in AD are mimicked in mouse models with massive amyloid loads. Focusing on secreted matrix and signaling proteins that increased in AD and the aged APP mouse brain, we establish that many of these proteins are within amyloid plaques, present in cerebrovascular amyloid, accumulate in dystrophic neurites, increased in reactive astrocytes, or some combination of these. Some proteins are known or suspected heparan sulfate binding proteins, but many can be shown to bind fibrillar Aβ and AVS peptide amyloid fibril in vitro. Consistent with this data, midkine (MDK) and pleiotrophin (PTN) accumulate in transthyretin cardiac amyloid and MDK in pancreatic amylin amyloid. Overexpression of MDK and PTN in APP mice alters the spatiotemporal accumulation of Aβ driving dramatic increases in CAA. MDK, PTN and SMOC1 also influence kinetics of Aβ aggregation in vitro. These data establish that i) many proteomic changes observed in human AD can be attributed to amyloid deposition and ii) that amyloid structures can scaffold the co-accumulation of many signaling proteins. Further, for the first two proteins investigated, we show that overexpression alters Aβ amyloid deposition. These data reinforce the role of amyloid in AD and other disorders but suggest that downstream pathology induced by amyloid is incredibly complex and that important pathophysiologic changes may be mediated by other co-accumulating proteins. Indeed, perhaps rather than direct toxicity is it is the scaffolding function of amyloid which results in sequestration of numerous signaling molecules that truly drives the pathophysiologic cellular responses that lead to organ failure.

Hide